This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stovroff, M. C. Articles by Norton, J. A. Search for Related Content PubMed PubMed Citation Articles by Stovroff, M. C. Articles by Norton, J. A.

Cachectin/Tumor Necrosis Factor: A Possible Mediator of Cancer Anorexia in the Rat¹

Surgical Metabolism Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892

Cachectin/tumor necrosis factor (TNF) is a macrophage product which may have a role in cancer cachexia. Recombinant human cachectin/TNF (Cetus Corporation) was administered i.p. twice daily to male F344 rats at varying, nonlethal dosages for either 5 or 10 days, and daily rat food intake and body weight were measured. There was a dose-dependent cachectin/TNF-induced decline in food intake and body weight gain over the treatment period. However, after 1 day rats became tolerant to these effects and increased food intake and gained body weight despite receiving cachectin/TNF. Rats were subsequently inoculated with a transplantable methylcholanthrene-induced sarcoma, and survival was measured. Rats previously treated with high-dose (either 100 or 200 µg/kg/day) cachectin/TNF survived significantly longer following tumor inoculation than did control rats given saline or rats given 10 µg/kg/day of cachectin/TNF. Analysis of tumor growth curves and tumor weight indicated that high-dose cachectin pretreatment did not retard tumor growth. Analysis of food intake and tumor burden following tumor inoculation indicated that high-dose cachectin pretreatment decreased the reduction in food intake associated with progressive tumor growth and allowed rats to withstand a greater tumor burden at death. Rats immunized with low-dose human cachectin/TNF developed high IgG titers against human TNF, but failed to demonstrate the same protection against a methylcholanthrene-induced tumor challenge as rats made tolerant with repetitive twice daily high-dose cachectin/TNF. The observation of reduced cancer-associated anorexia and increased survival of tumor-bearing rats associated with previous tolerance to exogenous cachectin/TNF strengthens the contention that endogenously produced cachectin may be a factor in the pathogenesis of cancer anorexia in the tumor-bearing rat. The mechanism of this tolerance is unclear but does not appear to be a humoral immune response.

¹ This work was presented in part at the 73rd meeting of the American College of Surgeons, San Francisco, CA.

Received 2/ 5/88. Revised 5/12/88. Accepted 5/20/88.

This article has been cited by other articles:

				W. Wang, C. Lonnroth, E. Svanberg, and K. Lundholm Cytokine and Cyclooxygenase-2 Protein in Brain Areas of Tumor-bearing Mice with Prostanoid-related Anorexia Cancer Res., June 1, 2001; 61(12): 4707 - 4715. [Abstract] [Full Text] [PDF]